Our findings are in agreement with previous studies in prostate cancer, where, although the ODC1 SNP was not significantly associated with risk, the effect of long-term DFMO treatment on patients with AG/AA genotypes resulted in a reduced prostate volume [25]. The gene discussed is ODC1; the disease is prostate cancer.